Author Archive: George Goodno

George Goodno

George is the Director of State Policy Communications at BIO and enjoys the opportunity to advocate for and educate audiences about the positive societal and economic impact of the bioscience industry. Another great aspect of his job is getting to work with BIO’s broad network of state bioscience associations to help advance legislative and regulatory initiatives that will continue to improve this high-skill, high-wage industry. In his spare time, he enjoys running, skiing, hiking, gardening, and most of all, spending time with his awesome wife and two daughters.

Follow him on Twitter @ggoodno


Latest Posts

Patent Reform in the News

© 2010 Opensourceway (CC 2.0 Attribution ShareAlike) (

The New York Post and The Washington Post have both run Op-eds in the last week addressing the need to reform the PTO’s inter partes review (IPR) process within current patent reform legislative efforts. Both opinions point to the weakness within the IPR process exposed by short selling practices of predatory hedge fund managers. Click on the links below to read more: From the New York Post: Hedge-fund investors are coming to raid your medicine cabinet. By Peter Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Investor Forum Closes with Record Attendance


The 14th Annual BIO Investor Forum wrapped up in San Francisco yesterday, having exceeded all previous attendance and participation records. The energy and buzz around #BIF15 is another sign of the continued strength and resilience of the biotech industry. This year’s forum brought together over 900 registered attendees and 175 presenting companies, facilitating 1700 meetings between investors and senior management for emerging and established biotechnology companies. Scott Whitaker, President of the BIO International Convention and Read More >

Events  |  Leave a comment  |  Email This Post

Fireside Chat: “Everything we knew in science 10 years ago is wrong.”


The speed of scientific innovation these days is comparable to the PC innovation era of the 1980s, according to Robert Nelsen of ARCH Venture Partners at today’s BIO Investor Forum fireside chat. This is not to say that he feels investing in biopharma is a short term game. Robert urged the audience to “keep their faith” in good science and the “good ideas will percolate up” to yield innovative breakthroughs. Having played a significant role Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Fireside Chat: James Noble Says Go for IPO


“Go for it,” was the parting advice James Noble, CEO and co-founder of Adaptimmune, had for pre-IPO biotech companies attending today’s BIO Investor Forum fireside chat. But, he said, be prepared for scrutiny from all sides… and mountains of paperwork. James co-founded Adaptimmune, a clinical-stage immunotherapy biopharmaceutical company, in July of 2008. At that time he was also part-time CEO of Immunocore, also a clinical-stage company engaged in T-cell receptor researches and develop. From this Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Politicking Biopharma Delays Cures

US Capitol Building

Forbes’ Matthew Herper ran a guest post from Robert Nelsen, cofounder and managing director of ARCH Venture Partners, which addresses the challenges our industry is currently facing amid the continued need for biomedical innovation. Read it here.

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,